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M A J O R A R T I C L E
All-Cause Gastroenteritis and Rotavirus-Coded
Hospitalizations Among US Children,
2000–2009
Rishi Desai,1 Aaron T. Curns,1 Claudia A. Steiner,2 Jacqueline E. Tate,1 Manish M. Patel,1 and Umesh D. Parashar1
1Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; and 2Healthcare Cost and Utilization Project, Center for
Delivery, Organizations, and Markets, Agency for Healthcare Research and Quality, US Department of Health and Human Services, Rockville, Maryland
Background. Rotavirus vaccine was recommended for US infants in 2006. We estimated baseline prevaccine
burden and monitored postvaccine trends in gastroenteritis-coded and rotavirus-coded hospitalizations among US
children.
Methods. We analyzed data from the State Inpatient Databases (SID) for 29–44 US states over a 10-year
period (2000–2009) to calculate gastroenteritis and rotavirus-coded hospitalization rates by age group, sex, and
region, among children <5 years of age. By extrapolating observed pre- and postvaccine gastroenteritis hospitaliza-
tion rates to the US population <5 years and based on the 2009 cost of a diarrhea hospitalization, we estimated
national reductions in diarrhea hospitalizations and associated treatment costs.
Results. The prevaccine (2000–2006) annual average gastroenteritis-coded hospitalization rate among children
<5 years of age was 74 per 10 000 (annual range, 71–82 per 10 000), and declined to 51 and 50 per 10 000 in 2008
and 2009, respectively (P < .001). The prevaccine (2000–2006) annual average rotavirus-coded hospitalization rate
among children <5 years of age was 15 per 10 000 (annual range, 13–18 per 10 000), and declined to 5 and 6 per
10 000 in 2008 and 2009, respectively (P < .001). The decreases in rotavirus-coded hospitalization rates in 2008
and 2009 compared with rates in prevaccine years were observed among all age groups and US regions. Nationally,
during 2008 and 2009 combined, we estimated a reduction of approximately 77 000 diarrhea hospitalizations and
approximately $242 million in hospital costs.
Conclusions. Since implementation of the US rotavirus vaccination program, a marked reduction in diarrhea
hospitalizations and related hospital charges has occurred among US children.
Prior to the introduction of rotavirus vaccine in the
United States in 2006, rotavirus gastroenteritis annual-
ly resulted in approximately 20–60 deaths, 55 000–
70000 hospitalizations, 200 000 emergency department
visits, and 400 000 outpatient visits among US chil-
dren <5 years of age, with direct medical costs of $300
million and total medical and societal costs of >$1
billion [1]. Currently, 2 rotavirus vaccines are available
in the United States—a pentavalent rotavirus vaccine
(RV5) (RotaTeq, Merck and Co) licensed in 2006 and
a monovalent rotavirus vaccine (RV1) (Rotarix, GSK
Biologicals) licensed in 2008.
Previous studies have shown that implementation of
the rotavirus vaccine program has led to a dramatic
decline in rotavirus disease burden and acute care utili-
zation for gastroenteritis in US children [2–4]. These
studies have been based on data from large discharge
databases, sentinel laboratories, sentinel hospital net-
works with active surveillance for laboratory-confirmed
rotavirus disease, or insurance claims data. They all ex-
amined data through the 2008 rotavirus season, the first
year that vaccine uptake was widespread. However,
there have been few comprehensive evaluations of hos-
pitalizations and hospital charges for diarrhea through
2009 using robust and nationally representative dis-
charge abstract data [2, 5]. Such an analysis is needed to
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confirm the trends observed through 2008 and determine
whether they have continued, given the year-to-year variation
in rotavirus trends before and after vaccine introduction [6].
We examined complete hospital discharge data from 29–44
US states that covered 81%–96% of the US birth cohort to
examine gastroenteritis- and rotavirus-coded hospitalizations
from January 2000 through December 2009. Our objectives
were to examine trends in gastroenteritis- and rotavirus-coded
hospitalizations at national and regional levels before and after
rotavirus vaccine introduction in the United States through
2009, and to provide estimates of reduction in hospital costs
following introduction of the vaccine.
METHODS
Data Source
We analyzed data from the State Inpatient Databases (SID) over a
10-year period (2000–2009) [7] to identify gastroenteritis- and ro-
tavirus-coded hospitalization records among children <5 years of
age. The SID is a component of the Healthcare Cost and Utiliza-
tion Project (HCUP) produced by the Agency for Healthcare Re-
search and Quality (AHRQ) and captures all hospitalizations that
occur in community hospitals in the participating states (ie, it is
not a sample of hospital discharges). The number of states partic-
ipating in the intramural SID has increased over time, with 29
states representing 81% of the US birth cohort participating in
2000, and 44 states representing 96% of the US birth cohort par-
ticipating by 2009 [7]. Our SID analysis was based on aggregated
data, so we used the Nationwide Inpatient Sample (NIS) to esti-
mate annual mean costs for a gastroenteritis-coded hospitalization
among children <5 years of age. The NIS is a nationally represen-
tative inpatient care database that is based on data from the SID,
containing data from approximately 8 million hospital stays each
year, which can be up-weighted to generate national estimates [8].
The 2009 NIS contains all discharge data from 1050 hospitals
located in 44 states, approximating a 20% stratified sample of US
community hospitals. HCUP data from 18 states have been previ-
ously used to demonstrate postvaccine reductions in rotavirus
hospitalizations [9]; our aim was to reaffirm these findings in a
more nationally representative sample and determine whether re-
ductions persisted in 2 postvaccine rotavirus seasons. Because all
hospitalization data were de-identified, hospital discharge records
were the unit of analysis in this study and informed consent was
not required. This study was conducted through an active collab-
oration between the Centers for Disease Control and Prevention
and the AHRQ.
Definition of Gastroenteritis and Rotavirus-Coded
Hospitalizations
Gastroenteritis hospitalizations were defined as hospital dis-
charges that included any of the following International
Classification of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) codes: diarrhea of determined etiology (bacterial
[001–005 and 008.0–008.5, excluding 003.2]; parasitic [006–
007, excluding 006.3–006.6]; and viral [008.6 and 008.8]), and
diarrhea of undetermined etiology (presumed infectious
[009.0–009.3] and presumed noninfectious [558.9 and
787.91]) [10]. Rotavirus-coded hospitalizations were a subset
of gastroenteritis hospitalizations that included the specific
ICD-9-CM code for rotavirus (008.61) [10]. Discharge records
were queried for a gastroenteritis or rotavirus ICD-9-CM code
through the first 15 diagnosis fields that are used by all partic-
ipating US states.
Demographic and Other Characteristics
Gastroenteritis- and rotavirus-coded hospitalizations for the
years 2000–2009 were examined by sex, US Census region
(Midwest, Northeast, South, and West), month and year of
discharge, and age group by month for children <5 years of
age (0–2, 3–5, 6–11, 12–17, 18–23, 24–35, 36–47, and 48–59
months). Hospitalizations with missing information for a spe-
cific variable were excluded from analysis of that variable but
were included for all other analyses.
Rate Calculations and Pre- and Postvaccine Comparisons
Hospitalization rates were calculated using the National
Center for Health Statistics’ Bridged Race postcensal under-5
population estimates for 2000 through 2009 [11]. The number
of hospitalizations with an ICD-9-CM code for gastroenteritis
or rotavirus was divided by the number of children <5 years
of age in states participating in the SID. Eighteen states did
not continuously participate in the SID for the entire time
period (Supplementary Table 1). The denominators for calcu-
lating rates, both nationally and regionally, were adjusted to
reflect the inclusion or exclusion of these states for a given
calendar year. Hospitalization rates were calculated by month,
age group, sex, and region. In addition, monthly hospi-
talization rates were calculated for the United States and by
region.
To compare the relative difference in pre-and postvaccine
years, gastroenteritis and rotavirus-coded hospitalization rates
for calendar years 2000–2006 were compared with the rates in
2008 and 2009 using χ2 tests. Data from 2007 were excluded
because rotavirus vaccine uptake was low and uneven during
the first year after vaccine introduction.
Hospital Stay and Costs
Median length of stay and hospital costs for gastroenteritis-
coded hospitalizations were examined and compared using
SID and NIS, respectively. The annual Consumer Price Index
for Medical Care was used to correct for inflation, and all hos-
pital costs are presented in 2009 US dollars [12].
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National Estimates of Reduction in Gastroenteritis
Hospitalizations and Charges After Rotavirus Vaccine
Implementation
National estimates of gastroenteritis hospitalizations were ob-
tained for each year by multiplying the estimated number of
resident children <5 years of age by gastroenteritis hospitaliza-
tion rates estimated from the SID data. The reduction in the
number of gastroenteritis hospitalizations nationally in 2008
and 2009 relative to the median number in prevaccine years
(2000–2006) was multiplied by the 2008 and 2009 annual
mean costs, respectively, to estimate the combined cost savings
due to averted gastroenteritis hospitalizations.
Results
All-Cause Gastroenteritis Hospitalization Trends Pre‐ and Post‐
Rotavirus Vaccine Implementation
There were 1 153 300 gastroenteritis-coded hospitalizations
between 2000 and 2009 in the HCUP database. The prevac-
cine (2000–2006) annual average gastroenteritis hospitaliza-
tion rate among children <5 years of age was 74 per 10 000
(annual range, 71–82 per 10 000); this rate declined 31% to 51
per 10 000 in 2008 and 33% to 50 per 10 000 in 2009 (P < .001
for both years) (Table 1). In both postvaccine years, rates
declined similarly in males and females. Of note, in 2008
declines were similar across the groups aged 3–59 months,
whereas in 2009 the declines in 3–23-month-old children were
greater than those among children 24 months and older. Ad-
ditionally, decreases in gastroenteritis-coded hospitalization
rates compared with the rate for the prevaccine years were ob-
served in all US regions; the decline was slightly lower in the
West compared with other regions in 2008, but in 2009 all
regions had a similar decline.
Rotavirus-Coded Hospitalization Trends Pre‐ and Post‐Rotavirus
Vaccine Implementation
There were 212 077 rotavirus-coded hospitalizations between
2000 and 2009 in the HCUP database, which is approximately
20% of all coded gastroenteritis discharges. The prevaccine
(2000–2006) average annual rotavirus-coded hospitalization
rate among children <5 years of age was 15 per 10 000 (annual
range, 13–18 per 10 000); this rate declined 71% to 4 per 10
000 in 2008 and 62% to 6 per 10 000 in 2009 (P < .001 for
both years) (Table 2). The declines were similar among males
and females in both years. In prevaccine years (2001–2006),
the annual average rotavirus-coded hospitalization rate was
Table 1. Gastroenteritis-Coded Hospitalization Rates in the Prevaccine Years (2000–2006) and Rates and Rate Reduction in
Postvaccine Years (2008 and 2009)a
2000–2006 2008 2009
Rate, Average Annual (Minimum-
Maximum) Hospitalizations per
10 000 Childrenb
Rate,
Hospitalizations per
10 000 Childrenb
Rate
Reduction
(%)
Rate,
Hospitalizations per
10 000 Childrenb
Rate
Reduction
(%)
Total 74 (71–82) 51 31 50 33
Sex
Male 79 (76–88) 54 31 53 33
Female 69 (67–76) 47 32 46 33
Age
0–2 months 163 (149–188) 130 20 124 24
3–5 months 125 (113–144) 89 29 81 35
6–11 months 142 (129–156) 91 36 81 43
12–17 months 122 (113–133) 78 36 69 43
18–23 months 89 (80–98) 58 34 56 37
24–35 months 53 (49–58) 37 30 40 25
36–47 months 32 (29–37) 22 31 27 15
48–59 months 23 (21–26) 16 30 18 22
Region
Midwest 71 (66–77) 46 35 50 30
Northeast 79 (72–88) 55 30 53 33
South 86 (80–96) 58 33 56 35
West 57 (53–63) 42 27 38 33
a Primary data obtained from Healthcare Cost and Utilization Project State Inpatient Databases Documentation. March 2011. Agency for Healthcare Research and
Quality.
b Rates represent gastroenteritis hospitalizations per 10 000 children <5 years of age.
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highest among children 6–11 months at 36 per 10 000 (annual
range, 34–39 per 100 000); rates in this age group declined
82% to 7 and 83% to 6 per 10 000 in 2008 and 2009, respec-
tively (P < .001). Of note, among children 24–59 months of
age, in 2009 there were smaller declines in rotavirus-coded
hospitalization rates of 7%–35% compared to much larger de-
clines of 55%–72% in 2008. In the prevaccine (2001–2006)
years, among children <5 years of age hospitalized with rotavi-
rus-coded diarrhea, 24% (annual range, 21%–26%) were
24–59 months of age. This proportion increased to 33% in
2008 and 48% in 2009, respectively (P < .001). Additionally,
decreases in rotavirus-coded hospitalization rates were
observed in all US regions; the decline was slightly lower in
the West compared with other regions in 2008 but in 2009
the West had the greatest decline.
Seasonal Patterns of Gastroenteritis and Rotavirus-Coded
Hospitalizations Pre– and Post–Rotavirus Vaccine
Implementation
In prevaccine years, the median monthly gastroenteritis-coded
hospitalization rate was highest in March at 152 per 10 000
(annual range, 118–172 per 10 000). After vaccine introduction,
gastroenteritis-coded hospitalization rates peaked at 69 per
10 000 in April 2008 and 89 per 10 000 in March 2009
(Figure 1A). In prevaccine years, the median monthly rotavirus-
coded hospitalization rate was highest in March at 54 per 10
000 (annual range, 33–63 per 10 000) (Figure 1B). After vaccine
introduction, rotavirus-coded hospitalization rates peaked at 14
per 10 000 in April 2008 and 20 per 10 000 in March 2009.
During each of the 4 months from January through April with
highest prevaccine rotavirus-coded hospitalization rates, the
rates in both 2008 and 2009 were substantially lower. However,
because of a delay in the onset of the 2008 rotavirus season,
rotavirus-coded hospitalization rates during May and June of
2008 exceeded prevaccine rates, although rates in these 2
months were substantially lower than during the peak months
from January through April.
Gastroenteritis Hospitalization Costs and Length of Stay
The median hospital cost for a gastroenteritis hospitalization
in adjusted 2009 dollars increased during the study period
from $1469 in 2000 to $3210 in 2009. The median length of
stay for a gastroenteritis-coded hospitalization was relatively
stable during the study period, ranging from 2.2 to 2.6 days.
Table 2. Rotavirus-Coded Hospitalization Rates in the Prevaccine Years (2000–2006) and Rates and Rate Reduction in Postvaccine
Years (2008 and 2009)a
2000–2006 2008 2009
Rate, Average Annual (Minimum-
Maximum) Hospitalizations per
10 000 Childrenb
Rate,
Hospitalizations per
10 000 Childrenb
Rate
Reduction
(%)
Rate,
Hospitalizations per
10 000 Childrenb
Rate
Reduction
(%)
Total 15 (13–18) 4 71 6 62
Sex
Male 17 (14–20) 5 71 6 62
Female 14 (11–17) 4 71 5 63
Age
0–2 months 19 (16–23) 7 61 8 57
3–5 months 24 (21–27) 5 78 5 81
6–11 months 36 (34–39) 7 82 6 83
12–17 months 32 (25–40) 8 76 8 76
18–23 months 22 (16–29) 8 64 8 62
24–35 months 11 (8–14) 5 55 7 35
36–47 months 5 (3–6) 2 64 4 7
48–59 months 2 (2–3) 1 72 2 22
Region
Midwest 18 (13–22) 4 75 8 56
Northeast 12 (8–15) 3 74 5 61
South 15 (12–21) 5 65 7 54
West 10 (8–11) 4 58 3 70
a Primary data obtained from Healthcare Cost and Utilization Project State Inpatient Databases Documentation. March 2011. Agency for Healthcare Research and
Quality.
b Rates represent rotavirus-coded hospitalizations per 10 000 children <5 years of age.
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National Estimates of Reduction in Gastroenteritis
Hospitalizations and Charges After Rotavirus Vaccine
Implementation
Extrapolating the observed gastroenteritis hospitalization rates
in our study to the US population <5 years of age yields a
median of 145 051 gastroenteritis hospitalizations annually
in prevaccine years; this declined to 107 354 and 105 952
gastroenteritis hospitalizations in 2008 and 2009, respectively.
Combining the average charge per gastroenteritis hospita-
lization in 2008 ($3080) and 2009 ($3210) and the reduction
in gastroenteritis hospitalizations in 2008 (37 697) and 2009
(39 099) yields an overall reduction of $116 087 912 and
$125 488 241 in hospital charges in the United States in 2008
and 2009, respectively.
Figure 1. A, Gastroenteritis hospitalization rates in prevaccine years and postvaccine years (2008 and 2009) by month of year. B, Rotavirus hospitali-
zation rates in prevaccine years and postvaccine years (2008 and 2009) by month of year. Black line, 2000–2006 median; gray line, maximum-minimum
range. All rates are for children <5 years of age.
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DISCUSSION
Since implementation of the US rotavirus vaccination program
in 2006, a marked reduction in both gastroenteritis- and rota-
virus-coded hospitalizations and related direct medical costs
has occurred among US children <5 years of age. During the
2008 and 2009 postvaccine years, we observed annual reduc-
tions in all-cause gastroenteritis hospitalizations of 31%–33%
and reductions in rotavirus-coded hospitalizations of 62%–
71% compared with prevaccine years from 2000 to 2006.
Reductions in gastroenteritis- and rotavirus-coded hospitaliza-
tions occurred across all US census regions and among most
racial groups. The most notable decreases occurred during the
winter rotavirus season and among children 6–11 months of
age, a group with the highest rates of rotavirus disease in pre-
vaccine years and with greatest levels of vaccine coverage in
both years. These findings strongly suggest that the reductions
in gastroenteritis- and rotavirus-coded hospitalizations were
due to rotavirus vaccine, as opposed to unmeasured contempo-
raneous factors or changes in hospital coding practices. In the
2 postvaccine years 2008 and 2009 combined, we estimated
a reduction of approximately 77 000 hospitalizations for gas-
troenteritis, yielding a national reduction in hospital charges of
>$240 million.
While declines in gastroenteritis and rotavirus-coded hospi-
talizations were seen in both postvaccine years 2008 and 2009,
some differences were observed between the 2 years. In partic-
ular, large declines were seen across all age groups in 2008,
including among children 24 months and older who were not
age-eligible for rotavirus vaccination, whereas in 2009 the de-
clines in these older nonvaccine-eligible age groups were
much less prominent. The slight rebound in rotavirus hospi-
talization rates during 2009, particularly among children aged
24–59 months, has been seen in an analysis of hospital dis-
charge data from a network of US pediatric hospitals as well
as in prospective, population-based surveillance of laboratory-
confirmed rotavirus hospitalizations and emergency room
visits in 3 US counties [2, 5]. One possible explanation may be
that a markedly diminished 2008 season, as a result of indirect
protection of unvaccinated infants due to reduced rotavirus
transmission in the community (ie, herd immunity), resulted
in a larger susceptible cohort of unvaccinated older children
in 2009 that were not exposed to natural rotavirus infection in
the previous 2008 season. The increased pool of susceptible
individuals and herd immunity likely combine to generate a
biennial pattern which is superimposed on a general decreased
rotavirus disease trend after vaccine introduction. This pattern
of biennial epidemics was predicted by a mathematical model
of rotavirus dynamics [13] and is corroborated by laboratory-
based rotavirus surveillance showing a similar pattern in 2010
and 2011 [14]. Also, important regional differences were
observed in the postvaccine era. The rotavirus-coded hospital-
ization rate in the West lagged behind other regions in 2008
but was highest among all regions in 2009, a geographic
pattern consistent with previously published data on rotavirus
laboratory detections [15].
Prior evaluations of rotavirus vaccine impact in the United
States have been performed. A study evaluating the HCUP da-
tabase also demonstrated postvaccine reductions in rotavirus
hospitalizations, but only included 1 complete postvaccine
season and a limited number of US states [9]. Our study ad-
dresses both of these limitations, making this vaccine impact
analysis more reliable and generalizable to the entire US popu-
lation. Another analysis of private- and public-sector insurance
claims in the MarketScan databases estimated national reduc-
tions of 64 855 gastroenteritis hospitalizations and $278 million
in cost savings over the combined 2008 and 2009 rotavirus
seasons [4], estimates that were strikingly similar to those pre-
sented here. Finally, a study using a database of 62 US pediatric
hospitals found reductions in gastroenteritis hospitalizations of
50% and 29% in the 2008 and 2009 rotavirus seasons, respec-
tively, relative to prevaccine years [5]. Again, these figures are
similar to our estimates based on more robust and nationally
representative data of reductions in gastroenteritis hospitaliza-
tions in 2008 (31%) and 2009 (33%). Collectively, these findings
from multiple hospital-based and payer databases conclusively
demonstrate a reduction in gastroenteritis hospitalizations and
associated costs in 2 postvaccine rotavirus seasons.
The hospitalization data from the SID have limitations. First,
the rotavirus code has been shown to be specific for identifying
rotavirus laboratory-confirmed hospitalizations; however, rota-
virus-coded events underestimate the true burden of rotavirus
hospitalizations, because laboratory testing and coding for rota-
virus are not routinely performed for all patients with gastroen-
teritis [16, 17]. This is particularly true for rotavirus mortality
trends, which have been documented in the prevaccine era but
not in the postvaccine years [18]. Additionally, aggregate de-
identified patient data preclude analyses by vaccination status.
Because no patient-level data are available, a given patient
might have multiple gastroenteritis- and/or rotavirus-coded
hospitalizations reported. Secular variation may account for
part of the decrease in gastroenteritis- and rotavirus-coded hos-
pitalization rates; however, it is unlikely to account for the large
declines we consistently observed in 2 postvaccine years.
Finally, the national reduction in hospital charges must be com-
pared against the cost of the rotavirus vaccination program. An
evaluation performed in 2007 revealed that although the rotavi-
rus vaccine is unlikely to be cost-saving in the United States, it
may still be considered a cost-effective intervention [19].
In summary, we demonstrate a marked reduction in both
gastroenteritis- and rotavirus-coded hospitalizations and
related direct medical costs among US children through 2
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rotavirus seasons after vaccine implementation. Disease reduc-
tions were greatest among 0–23-month-old infants, compared
to older, largely unvaccinated birth cohorts, particularly in
2009. This suggests that gastroenteritis- and rotavirus-coded
hospitalization rates among children <5 years will continue to
decrease in future years, as successive birth cohorts are vacci-
nated. Ongoing surveillance will enable monitoring of the
long-term impact of vaccination on rotavirus hospitalizations
and associated costs.
Supplementary Data
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Supplemental Table 1. HCUP participating states and years of data inclusion from 
2000 through 2009 by US region 
Region 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 
Midwest WI WI WI WI WI WI WI WI WI WI 
Midwest IL IL IL IL IL IL IL IL IL IL 
Midwest MO MO MO MO MO MO MO MO MO MO 
Midwest IA IA IA IA IA IA IA IA IA IA 
Midwest KS KS KS KS KS KS KS KS KS KS 
Midwest MI MI MI MI MI MI MI MI MI MI 
Midwest   MN MN MN MN MN MN MN MN MN 
Midwest   NE NE NE NE NE NE NE NE NE 
Midwest     OH OH OH OH OH OH OH OH 
Midwest     SD SD SD SD SD SD SD SD 
Midwest       IN IN IN IN IN IN IN 
Northeast CT CT CT CT CT CT CT CT CT CT 
Northeast NY NY NY NY NY NY NY NY NY NY 
Northeast MA MA MA MA MA MA MA MA MA MA 
Northeast NJ NJ NJ NJ NJ NJ NJ NJ NJ NJ 
Northeast ME ME ME ME     ME ME ME ME 
Northeast PA PA PA PA         PA PA 
Northeast   RI RI RI RI RI RI RI RI RI 
Northeast   VT VT VT VT VT VT VT VT VT 
Northeast       NH NH NH NH NH NH NH 
South WV WV WV WV WV WV WV WV WV WV 
South FL FL FL FL FL FL FL FL FL FL 
South GA GA GA GA GA GA GA GA GA GA 
South KY KY KY KY KY KY KY KY KY KY 
South MD MD MD MD MD MD MD MD MD MD 
South NC NC NC NC NC NC NC NC NC NC 
South TX TX TX TX TX TX TX TX TX TX 
South SC SC SC SC SC SC SC SC SC SC 
South TN TN TN TN TN TN TN TN TN TN 
South VA VA VA VA VA   VA VA VA VA 
South         AR AR AR AR AR AR 
South           OK OK OK OK OK 
South                 LA LA 
West AZ AZ AZ AZ AZ AZ AZ AZ AZ AZ 
West CA CA CA CA CA CA CA CA CA CA 
West CO CO CO CO CO CO CO CO CO CO 
West HI HI HI HI HI HI HI HI HI HI 
West OR OR OR OR OR OR OR OR OR OR 
 West UT UT UT UT UT UT UT UT UT UT 
West WA WA WA WA WA WA WA WA WA WA 
West     NV NV NV NV NV NV NV NV 
West               WY WY WY 
West                   NM 
West                   MT 
